Cargando…
Novel polymeric inhibitors of HCoV-NL63
The human coronavirus NL63 is generally classified as a common cold pathogen, though the infection may also result in severe lower respiratory tract diseases, especially in children, patients with underlying disease, and elderly. It has been previously shown that HCoV-NL63 is also one of the most im...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V. Published by Elsevier B.V.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114096/ https://www.ncbi.nlm.nih.gov/pubmed/23201315 http://dx.doi.org/10.1016/j.antiviral.2012.11.006 |
_version_ | 1783513812163362816 |
---|---|
author | Milewska, Aleksandra Ciejka, Justyna Kaminski, Kamil Karewicz, Anna Bielska, Dorota Zeglen, Slawomir Karolak, Wojciech Nowakowska, Maria Potempa, Jan Bosch, Berend Jan Pyrc, Krzysztof Szczubialka, Krzysztof |
author_facet | Milewska, Aleksandra Ciejka, Justyna Kaminski, Kamil Karewicz, Anna Bielska, Dorota Zeglen, Slawomir Karolak, Wojciech Nowakowska, Maria Potempa, Jan Bosch, Berend Jan Pyrc, Krzysztof Szczubialka, Krzysztof |
author_sort | Milewska, Aleksandra |
collection | PubMed |
description | The human coronavirus NL63 is generally classified as a common cold pathogen, though the infection may also result in severe lower respiratory tract diseases, especially in children, patients with underlying disease, and elderly. It has been previously shown that HCoV-NL63 is also one of the most important causes of croup in children. In the current manuscript we developed a set of polymer-based compounds showing prominent anticoronaviral activity. Polymers have been recently considered as promising alternatives to small molecule inhibitors, due to their intrinsic antimicrobial properties and ability to serve as matrices for antimicrobial compounds. Most of the antimicrobial polymers show antibacterial properties, while those with antiviral activity are much less frequent. A cationically modified chitosan derivative, N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC), and hydrophobically-modified HTCC were shown to be potent inhibitors of HCoV-NL63 replication. Furthermore, both compounds showed prominent activity against murine hepatitis virus, suggesting broader anticoronaviral activity. |
format | Online Article Text |
id | pubmed-7114096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Elsevier B.V. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71140962020-04-02 Novel polymeric inhibitors of HCoV-NL63 Milewska, Aleksandra Ciejka, Justyna Kaminski, Kamil Karewicz, Anna Bielska, Dorota Zeglen, Slawomir Karolak, Wojciech Nowakowska, Maria Potempa, Jan Bosch, Berend Jan Pyrc, Krzysztof Szczubialka, Krzysztof Antiviral Res Article The human coronavirus NL63 is generally classified as a common cold pathogen, though the infection may also result in severe lower respiratory tract diseases, especially in children, patients with underlying disease, and elderly. It has been previously shown that HCoV-NL63 is also one of the most important causes of croup in children. In the current manuscript we developed a set of polymer-based compounds showing prominent anticoronaviral activity. Polymers have been recently considered as promising alternatives to small molecule inhibitors, due to their intrinsic antimicrobial properties and ability to serve as matrices for antimicrobial compounds. Most of the antimicrobial polymers show antibacterial properties, while those with antiviral activity are much less frequent. A cationically modified chitosan derivative, N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC), and hydrophobically-modified HTCC were shown to be potent inhibitors of HCoV-NL63 replication. Furthermore, both compounds showed prominent activity against murine hepatitis virus, suggesting broader anticoronaviral activity. Elsevier B.V. Published by Elsevier B.V. 2013-02 2012-11-28 /pmc/articles/PMC7114096/ /pubmed/23201315 http://dx.doi.org/10.1016/j.antiviral.2012.11.006 Text en Copyright © 2012 Elsevier B.V. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Milewska, Aleksandra Ciejka, Justyna Kaminski, Kamil Karewicz, Anna Bielska, Dorota Zeglen, Slawomir Karolak, Wojciech Nowakowska, Maria Potempa, Jan Bosch, Berend Jan Pyrc, Krzysztof Szczubialka, Krzysztof Novel polymeric inhibitors of HCoV-NL63 |
title | Novel polymeric inhibitors of HCoV-NL63 |
title_full | Novel polymeric inhibitors of HCoV-NL63 |
title_fullStr | Novel polymeric inhibitors of HCoV-NL63 |
title_full_unstemmed | Novel polymeric inhibitors of HCoV-NL63 |
title_short | Novel polymeric inhibitors of HCoV-NL63 |
title_sort | novel polymeric inhibitors of hcov-nl63 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114096/ https://www.ncbi.nlm.nih.gov/pubmed/23201315 http://dx.doi.org/10.1016/j.antiviral.2012.11.006 |
work_keys_str_mv | AT milewskaaleksandra novelpolymericinhibitorsofhcovnl63 AT ciejkajustyna novelpolymericinhibitorsofhcovnl63 AT kaminskikamil novelpolymericinhibitorsofhcovnl63 AT karewiczanna novelpolymericinhibitorsofhcovnl63 AT bielskadorota novelpolymericinhibitorsofhcovnl63 AT zeglenslawomir novelpolymericinhibitorsofhcovnl63 AT karolakwojciech novelpolymericinhibitorsofhcovnl63 AT nowakowskamaria novelpolymericinhibitorsofhcovnl63 AT potempajan novelpolymericinhibitorsofhcovnl63 AT boschberendjan novelpolymericinhibitorsofhcovnl63 AT pyrckrzysztof novelpolymericinhibitorsofhcovnl63 AT szczubialkakrzysztof novelpolymericinhibitorsofhcovnl63 |